With its uniquely engineered Fc region, tislelizumab has the potential to avoid this adverse effect of effector T-cell depletion by CD64+ Mφ, while retaining their pro-inflammatory anti-tumor activity. The gene discussed is FCGR1A; the disease is neoplasm.